Home | Welcome to Contract Pharma   
Last Updated Thursday, August 21 2014
Print

Financial Reports: Biogen Idec



Published April 25, 2013
Biogen Idec 1Q13

1Q Revenues: $1.4 billion (+10%)

1Q Earnings: $427 million (+41%)

Comments: Avonex sales rose 13% ($746 million), Tysabri rose 9% ($312 million), Fampyra was up 54% ($23 million) and Fumaderm was up 8% ($14 million). Rituxan revenues from its joint business arrangement fell 7% to $265 million.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On